πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 429 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11766032

Genetically modified non-human animals expressing human EPO

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11739162

Side chain modified peptoids useful as structure-stabilizing coatings for biomaterials

The Regents of the University of California Β· Granted Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11684572

Methods for producing carboxylate ligand modified ferric iron hydroxide colloids and relat

United Kingdom Research and Innovation Β· Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11633488

Modified IL-2 polypeptides and uses thereof

Bright Peak Therapeutics AG Β· Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11629348

Linkage modified oligomeric compounds and uses thereof

Ionis Pharmaceuticals, Inc. Β· Granted Tue Apr 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11622547

Genetically modified mouse that expresses human albumin

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11613744

Modified urokinase-type plasminogen activator polypeptides and methods of use

Vertex Pharmaceuticals Incorporated Β· Granted Tue Mar 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11603392

Vault particles having a modified R8 flexible region

The Regents of the University of California Β· Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11597853

Coatings containing polymer modified enzyme for stable self-cleaning of organic stains

Regents of the University of Minnesota Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11583556

Modified cells and methods of therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11576984

Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11576356

Genetically modified non-human animals and methods of use thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11566149

Coatings containing polymer modified enzyme for stable self-cleaning of organic stains

Regents of the University of Minnesota Β· Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11548852

Modified amino acids

Sutro Biopharma, Inc. Β· Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11549109

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11549110

Modified short interfering nucleic acid (siNA) molecules and uses thereof

Aligos Therapeutics, Inc. Β· Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11535773

Coatings containing polymer modified enzyme for stable self-cleaning of organic stains

Regents of the University of Minnesota Β· Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11535870

Adeno-associated virus vectors encoding modified G6PC and uses thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11504391

Modified RNA agents with reduced off-target effect

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11491212

Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia

Catalyst Biosciences, Inc. Β· Granted Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11466274

Modified gapmer oligonucleotides and methods of use

Aligos Therapeutics, Inc. Β· Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11453861

Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

Precision BioSciences, Inc. Β· Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11427822

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11419318

Genetically modified rat comprising a humanized TRKB locus

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted